Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.306 SEK | +4.26% | +7.37% | -24.91% |
Mar. 26 | Transcript : Vivesto AB - Special Call | |
Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Sales 2021 | 28.87M 2.67M | Sales 2022 | 3.04M 281K | Capitalization | 234M 21.59M |
---|---|---|---|---|---|
Net income 2021 | -133M -12.3M | Net income 2022 | -357M -33.01M | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 8.03M | Net cash position 2022 | 134M 12.42M | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Vivesto AB
1 day | +4.26% | ||
1 week | +7.37% | ||
Current month | +9.09% | ||
1 month | +0.82% | ||
3 months | -22.14% | ||
6 months | +58.71% | ||
Current year | -24.91% |
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 0.306 | +4.26% | 733,556 |
24-05-02 | 0.2935 | +4.63% | 270,776 |
24-04-30 | 0.2805 | -1.23% | 280,714 |
24-04-29 | 0.284 | -0.35% | 348,759 |
24-04-26 | 0.285 | -1.55% | 492,006 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.91% | 15.24M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- VIVE Stock